Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Transplantation. 2019 Aug;103(8):1655-1662. doi: 10.1097/TP.0000000000002548.
Although chronic kidney disease (CKD) is still a common complication, the prognosis of kidney function after liver transplantation (LT) is not well known. Moreover, kidney function after LT in children with renal involvement is unknown.
We retrospectively analyzed patients aged <20 years who underwent LT between November 2005 and March 2015 at our institute.
The cohort included 313 pediatric LT recipients (135 males). The median age at LT was 1.1 years (interquartile range, 0.6 to 4.8 y), and the median duration of follow-up was 3.8 years (interquartile range, 1.7 to 6.2 y). We divided the patients by their primary disease into BA (biliary atresia), non-BA (other liver disease without primary renal involvement), or KD (patients with a pre-existing kidney disease) group, which comprised 141, 141, and 31 patients, respectively. Eight-year renal survival with stage 3 CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m) as the event was 99.2%, 92.4%, and 47.7% for the BA, non-BA, and KD group, respectively. Multivariate analysis disclosed primary kidney disease and multiple acute rejections as independent predictors of renal survival. The KD group showed no increase in the rate of kidney function deterioration after LT.
Eight-year renal survival with stage 3 CKD, particularly in patients with non-pre-existing KD, exceeded 92.0%, and end-stage kidney disease developed in only one patient. Kidney function can be highly preserved following LT even in patients with KD, provided that LT is not contraindicated in patients with renal involvement receiving optimal immunosuppressive management.
虽然慢性肾脏病(CKD)仍然是常见的并发症,但肝移植(LT)后肾功能的预后尚不清楚。此外,儿童肾受累患者 LT 后肾功能也不明确。
我们回顾性分析了 2015 年 3 月前在我院接受 LT 的年龄<20 岁的患者。
该队列包括 313 例儿科 LT 受者(135 例男性)。LT 时的中位年龄为 1.1 岁(四分位距 0.6-4.8 岁),中位随访时间为 3.8 年(四分位距 1.7-6.2 年)。我们根据原发病将患者分为 BA(胆道闭锁)、非-BA(无原发性肾受累的其他肝病)或 KD(存在原有肾脏疾病)组,分别有 141、141 和 31 例患者。以 CKD 3 期(估算肾小球滤过率<60mL/min/1.73m)为事件的 8 年肾脏存活率分别为 BA、非-BA 和 KD 组的 99.2%、92.4%和 47.7%。多变量分析显示,原发病和多次急性排斥反应是肾脏存活率的独立预测因素。KD 组 LT 后肾功能恶化的发生率没有增加。
KD 患者中 8 年 CKD 3 期的肾脏存活率,特别是在无原有 KD 的患者中,超过 92.0%,仅有 1 例患者发展为终末期肾病。在接受最佳免疫抑制治疗的肾受累患者中,如果 LT 不被禁忌,LT 后肾功能可得到高度保留。